London Borough of Lambeth is procuring two Approved Provider Lists (APL) for the provision of bed-based placements for adults with learning disabilities and/or autism. Providers who are part of this APL will provide residential care and/or supported living placements for Lambeth...
London Borough of Tower Hamlets is committed to developing a thriving Voluntary and Community Sector (VCS) sector to assist with shaping its strategic vision and supporting the delivery of key priorities for children, young people and families. The local VCS sector is a valuable...
This procurement activity is hosted by University Hospitals Birmingham NHS Foundation Trust (the “Authority”) on behalf of the NHS England, for the requirement of a Midlands Critical Care Transfer Services Ambulance Provider.
This service covers the ambulance provider provision...
The London Borough of Lambeth Council seek to establish a contract for the commission of up to four local providers to deliver Supported Employment provision through the targeted Individual Placement and Support (IPS) 'Place and Train' model. This model is designed to...
Westminster City Council and the Royal Borough of Kensington and Chelsea are seeking an independent consultancy to undertake a review of the current adult drug and alcohol treatment and recovery systems. The review will assess current service provision, undertake stakeholder and...
The London Borough of Camden are seeking to award a contract for the provision of the Young People's Supported Accommodation Pathway - Mixed Support service. This service contract is for young people aged 16–25-year-olds who require accommodation and support who are: • Children...
Buyer
London Borough of Camden
Location
London
Deadline
Closes 12 Oct 2026
Value
£2.7m
Key dates and value
Status
Closed
Submission deadline
8 Jul 2026
Published
4 Jun 2026
Estimated value
£26.1m
Location
London, London
Buyer type
NHS Trust
Overview
Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.
CPV codes
85100000 Health services
About the buyer
NHS England has published 441 tender notices since 7 Oct 2023, with a combined advertised value of £118bn. 63 of them are currently open.
How to apply
Tender documents and submissions are handled on the official portal (Find a Tender). Register there to download the documents and submit your response before the deadline.
Upload the tender documents and mytender.io drafts compliant answers from your own past bids, case studies and policies, so your team spends its time improving the bid rather than starting from a blank page.
Source: Find a Tender. Contains public sector information licensed under the Open Government Licence v3.0. Details may change; always check the original notice before bidding.